Bellevue Group’s Gilead Sciences GILD Stock Holding History

Bellevue Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-600	Closed	-$174K	–	207
2019 Q1	$174K	Buy	+600	New	+$39.9K	0.01%	135

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group's GILD Position: Q2 2026 in Review

Bellevue Group increased its Gilead Sciences (GILD) stake by 85% in Q2 2026, buying an estimated $130M and bringing the position to 2,158,772 shares worth $273M. The position accounts for 5.74% of the portfolio, ranked #4.

Bellevue Group first reported a position in GILD in Q1 2016 and has held it in 42 quarters since. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Bellevue Group held 2,158,772 shares of Gilead Sciences worth $273M as of Q2 2026.
Bellevue Group bought 988,893 Gilead Sciences shares in Q2 2026, an estimated $130M.
Gilead Sciences made up 5.74% of Bellevue Group's portfolio in Q2 2026, its #4 holding.
Bellevue Group first reported a position in Gilead Sciences in Q1 2016 and has held it in 42 quarters since.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.